Global Metabolic Disorders Therapeutics Market Research Report 2023

Report ID: 1974769 | Published Date: Jan 2025 | No. of Page: 94 | Base Year: 2024 | Rating: 4.8 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Report Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
        1.2.2 Metachromatic Leukodystrophy
        1.2.3 Globoid Leukodystrophy
        1.2.4 Hepatic Encephalopathy
        1.2.5 Others
    1.3 Market by Application
        1.3.1 Global Metabolic Disorders Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
        1.3.2 Diabetes
        1.3.3 Obesity
        1.3.4 Hypercholesterolemia
        1.3.5 Lysosomal Storage Diseases
        1.3.6 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Metabolic Disorders Therapeutics Market Perspective (2017-2028)
    2.2 Metabolic Disorders Therapeutics Growth Trends by Region
        2.2.1 Metabolic Disorders Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
        2.2.2 Metabolic Disorders Therapeutics Historic Market Size by Region (2017-2022)
        2.2.3 Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028)
    2.3 Metabolic Disorders Therapeutics Market Dynamics
        2.3.1 Metabolic Disorders Therapeutics Industry Trends
        2.3.2 Metabolic Disorders Therapeutics Market Drivers
        2.3.3 Metabolic Disorders Therapeutics Market Challenges
        2.3.4 Metabolic Disorders Therapeutics Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Metabolic Disorders Therapeutics Players by Revenue
        3.1.1 Global Top Metabolic Disorders Therapeutics Players by Revenue (2017-2022)
        3.1.2 Global Metabolic Disorders Therapeutics Revenue Market Share by Players (2017-2022)
    3.2 Global Metabolic Disorders Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Metabolic Disorders Therapeutics Revenue
    3.4 Global Metabolic Disorders Therapeutics Market Concentration Ratio
        3.4.1 Global Metabolic Disorders Therapeutics Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorders Therapeutics Revenue in 2021
    3.5 Metabolic Disorders Therapeutics Key Players Head office and Area Served
    3.6 Key Players Metabolic Disorders Therapeutics Product Solution and Service
    3.7 Date of Enter into Metabolic Disorders Therapeutics Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorders Therapeutics Breakdown Data by Type
    4.1 Global Metabolic Disorders Therapeutics Historic Market Size by Type (2017-2022)
    4.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028)
5 Metabolic Disorders Therapeutics Breakdown Data by Application
    5.1 Global Metabolic Disorders Therapeutics Historic Market Size by Application (2017-2022)
    5.2 Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
    6.1 North America Metabolic Disorders Therapeutics Market Size (2017-2028)
    6.2 North America Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
    6.3 North America Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
    6.4 United States
    6.5 Canada
7 Europe
    7.1 Europe Metabolic Disorders Therapeutics Market Size (2017-2028)
    7.2 Europe Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
    7.3 Europe Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
    7.4 Germany
    7.5 France
    7.6 U.K.
    7.7 Italy
    7.8 Russia
    7.9 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Metabolic Disorders Therapeutics Market Size (2017-2028)
    8.2 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
    8.3 Asia-Pacific Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
    8.4 China
    8.5 Japan
    8.6 South Korea
    8.7 Southeast Asia
    8.8 India
    8.9 Australia
9 Latin America
    9.1 Latin America Metabolic Disorders Therapeutics Market Size (2017-2028)
    9.2 Latin America Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
    9.3 Latin America Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
    9.4 Mexico
    9.5 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Metabolic Disorders Therapeutics Market Size (2017-2028)
    10.2 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2017-2022)
    10.3 Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2023-2028)
    10.4 Turkey
    10.5 Saudi Arabia
    10.6 UAE
11 Key Players Profiles
    11.1 AbbVie
        11.1.1 AbbVie Company Detail
        11.1.2 AbbVie Business Overview
        11.1.3 AbbVie Metabolic Disorders Therapeutics Introduction
        11.1.4 AbbVie Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.1.5 AbbVie Recent Development
    11.2 Novo Nordisk
        11.2.1 Novo Nordisk Company Detail
        11.2.2 Novo Nordisk Business Overview
        11.2.3 Novo Nordisk Metabolic Disorders Therapeutics Introduction
        11.2.4 Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.2.5 Novo Nordisk Recent Development
    11.3 Actelion Pharmaceuticals
        11.3.1 Actelion Pharmaceuticals Company Detail
        11.3.2 Actelion Pharmaceuticals Business Overview
        11.3.3 Actelion Pharmaceuticals Metabolic Disorders Therapeutics Introduction
        11.3.4 Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.3.5 Actelion Pharmaceuticals Recent Development
    11.4 Sanofi
        11.4.1 Sanofi Company Detail
        11.4.2 Sanofi Business Overview
        11.4.3 Sanofi Metabolic Disorders Therapeutics Introduction
        11.4.4 Sanofi Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.4.5 Sanofi Recent Development
    11.5 Biocon
        11.5.1 Biocon Company Detail
        11.5.2 Biocon Business Overview
        11.5.3 Biocon Metabolic Disorders Therapeutics Introduction
        11.5.4 Biocon Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.5.5 Biocon Recent Development
    11.6 Merck
        11.6.1 Merck Company Detail
        11.6.2 Merck Business Overview
        11.6.3 Merck Metabolic Disorders Therapeutics Introduction
        11.6.4 Merck Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.6.5 Merck Recent Development
    11.7 Boehringer Ingelheim
        11.7.1 Boehringer Ingelheim Company Detail
        11.7.2 Boehringer Ingelheim Business Overview
        11.7.3 Boehringer Ingelheim Metabolic Disorders Therapeutics Introduction
        11.7.4 Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.7.5 Boehringer Ingelheim Recent Development
    11.8 AstraZeneca
        11.8.1 AstraZeneca Company Detail
        11.8.2 AstraZeneca Business Overview
        11.8.3 AstraZeneca Metabolic Disorders Therapeutics Introduction
        11.8.4 AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.8.5 AstraZeneca Recent Development
    11.9 CymaBay Therapeutics
        11.9.1 CymaBay Therapeutics Company Detail
        11.9.2 CymaBay Therapeutics Business Overview
        11.9.3 CymaBay Therapeutics Metabolic Disorders Therapeutics Introduction
        11.9.4 CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.9.5 CymaBay Therapeutics Recent Development
    11.10 Eli Lilly and Company
        11.10.1 Eli Lilly and Company Company Detail
        11.10.2 Eli Lilly and Company Business Overview
        11.10.3 Eli Lilly and Company Metabolic Disorders Therapeutics Introduction
        11.10.4 Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2017-2022)
        11.10.5 Eli Lilly and Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Disclaimer
    13.3 Author Details

List of Tables
    Table 1. Global Metabolic Disorders Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
    Table 2. Key Players of Metachromatic Leukodystrophy
    Table 3. Key Players of Globoid Leukodystrophy
    Table 4. Key Players of Hepatic Encephalopathy
    Table 5. Key Players of Others
    Table 6. Global Metabolic Disorders Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
    Table 7. Global Metabolic Disorders Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
    Table 8. Global Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 9. Global Metabolic Disorders Therapeutics Market Share by Region (2017-2022)
    Table 10. Global Metabolic Disorders Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
    Table 11. Global Metabolic Disorders Therapeutics Market Share by Region (2023-2028)
    Table 12. Metabolic Disorders Therapeutics Market Trends
    Table 13. Metabolic Disorders Therapeutics Market Drivers
    Table 14. Metabolic Disorders Therapeutics Market Challenges
    Table 15. Metabolic Disorders Therapeutics Market Restraints
    Table 16. Global Metabolic Disorders Therapeutics Revenue by Players (2017-2022) & (US$ Million)
    Table 17. Global Metabolic Disorders Therapeutics Market Share by Players (2017-2022)
    Table 18. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Therapeutics as of 2021)
    Table 19. Ranking of Global Top Metabolic Disorders Therapeutics Companies by Revenue (US$ Million) in 2021
    Table 20. Global 5 Largest Players Market Share by Metabolic Disorders Therapeutics Revenue (CR5 and HHI) & (2017-2022)
    Table 21. Key Players Headquarters and Area Served
    Table 22. Key Players Metabolic Disorders Therapeutics Product Solution and Service
    Table 23. Date of Enter into Metabolic Disorders Therapeutics Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global Metabolic Disorders Therapeutics Market Size by Type (2017-2022) & (US$ Million)
    Table 26. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2017-2022)
    Table 27. Global Metabolic Disorders Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
    Table 28. Global Metabolic Disorders Therapeutics Revenue Market Share by Type (2023-2028)
    Table 29. Global Metabolic Disorders Therapeutics Market Size by Application (2017-2022) & (US$ Million)
    Table 30. Global Metabolic Disorders Therapeutics Revenue Market Share by Application (2017-2022)
    Table 31. Global Metabolic Disorders Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
    Table 32. Global Metabolic Disorders Therapeutics Revenue Market Share by Application (2023-2028)
    Table 33. North America Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 34. North America Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 35. Europe Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 36. Europe Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 37. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 38. Asia-Pacific Metabolic Disorders Therapeutics Market Size by Region (2023-2028) & (US$ Million)
    Table 39. Latin America Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 40. Latin America Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 41. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2017-2022) & (US$ Million)
    Table 42. Middle East & Africa Metabolic Disorders Therapeutics Market Size by Country (2023-2028) & (US$ Million)
    Table 43. AbbVie Company Detail
    Table 44. AbbVie Business Overview
    Table 45. AbbVie Metabolic Disorders Therapeutics Product
    Table 46. AbbVie Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 47. AbbVie Recent Development
    Table 48. Novo Nordisk Company Detail
    Table 49. Novo Nordisk Business Overview
    Table 50. Novo Nordisk Metabolic Disorders Therapeutics Product
    Table 51. Novo Nordisk Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 52. Novo Nordisk Recent Development
    Table 53. Actelion Pharmaceuticals Company Detail
    Table 54. Actelion Pharmaceuticals Business Overview
    Table 55. Actelion Pharmaceuticals Metabolic Disorders Therapeutics Product
    Table 56. Actelion Pharmaceuticals Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 57. Actelion Pharmaceuticals Recent Development
    Table 58. Sanofi Company Detail
    Table 59. Sanofi Business Overview
    Table 60. Sanofi Metabolic Disorders Therapeutics Product
    Table 61. Sanofi Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 62. Sanofi Recent Development
    Table 63. Biocon Company Detail
    Table 64. Biocon Business Overview
    Table 65. Biocon Metabolic Disorders Therapeutics Product
    Table 66. Biocon Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 67. Biocon Recent Development
    Table 68. Merck Company Detail
    Table 69. Merck Business Overview
    Table 70. Merck Metabolic Disorders Therapeutics Product
    Table 71. Merck Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 72. Merck Recent Development
    Table 73. Boehringer Ingelheim Company Detail
    Table 74. Boehringer Ingelheim Business Overview
    Table 75. Boehringer Ingelheim Metabolic Disorders Therapeutics Product
    Table 76. Boehringer Ingelheim Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 77. Boehringer Ingelheim Recent Development
    Table 78. AstraZeneca Company Detail
    Table 79. AstraZeneca Business Overview
    Table 80. AstraZeneca Metabolic Disorders Therapeutics Product
    Table 81. AstraZeneca Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 82. AstraZeneca Recent Development
    Table 83. CymaBay Therapeutics Company Detail
    Table 84. CymaBay Therapeutics Business Overview
    Table 85. CymaBay Therapeutics Metabolic Disorders Therapeutics Product
    Table 86. CymaBay Therapeutics Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 87. CymaBay Therapeutics Recent Development
    Table 88. Eli Lilly and Company Company Detail
    Table 89. Eli Lilly and Company Business Overview
    Table 90. Eli Lilly and Company Metabolic Disorders Therapeutics Product
    Table 91. Eli Lilly and Company Revenue in Metabolic Disorders Therapeutics Business (2017-2022) & (US$ Million)
    Table 92. Eli Lilly and Company Recent Development
    Table 93. Research Programs/Design for This Report
    Table 94. Key Data Information from Secondary Sources
    Table 95. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Metabolic Disorders Therapeutics Market Share by Type: 2021 VS 2028
    Figure 2. Metachromatic Leukodystrophy Features
    Figure 3. Globoid Leukodystrophy Features
    Figure 4. Hepatic Encephalopathy Features
    Figure 5. Others Features
    Figure 6. Global Metabolic Disorders Therapeutics Market Share by Application in 2021 & 2028
    Figure 7. Diabetes Case Studies
    Figure 8. Obesity Case Studies
    Figure 9. Hypercholesterolemia Case Studies
    Figure 10. Lysosomal Storage Diseases Case Studies
    Figure 11. Others Case Studies
    Figure 12. Metabolic Disorders Therapeutics Report Years Considered
    Figure 13. Global Metabolic Disorders Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
    Figure 14. Global Metabolic Disorders Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
    Figure 15. Global Metabolic Disorders Therapeutics Market Share by Region: 2021 VS 2028
    Figure 16. Global Metabolic Disorders Therapeutics Market Share by Players in 2021
    Figure 17. Global Top Metabolic Disorders Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Therapeutics as of 2021)
    Figure 18. The Top 10 and 5 Players Market Share by Metabolic Disorders Therapeutics Revenue in 2021
    Figure 19. North America Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 20. North America Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
    Figure 21. United States Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 22. Canada Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 23. Europe Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 24. Europe Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
    Figure 25. Germany Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 26. France Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 27. U.K. Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 28. Italy Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 29. Russia Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 30. Nordic Countries Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 31. Asia-Pacific Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 32. Asia-Pacific Metabolic Disorders Therapeutics Market Share by Region (2017-2028)
    Figure 33. China Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 34. Japan Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 35. South Korea Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 36. Southeast Asia Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 37. India Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 38. Australia Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 39. Latin America Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 40. Latin America Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
    Figure 41. Mexico Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 42. Brazil Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 43. Middle East & Africa Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 44. Middle East & Africa Metabolic Disorders Therapeutics Market Share by Country (2017-2028)
    Figure 45. Turkey Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 46. Saudi Arabia Metabolic Disorders Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
    Figure 47. AbbVie Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 48. Novo Nordisk Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 49. Actelion Pharmaceuticals Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 50. Sanofi Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 51. Biocon Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 52. Merck Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 53. Boehringer Ingelheim Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 54. AstraZeneca Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 55. CymaBay Therapeutics Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 56. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorders Therapeutics Business (2017-2022)
    Figure 57. Bottom-up and Top-down Approaches for This Report
    Figure 58. Data Triangulation
    Figure 59. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
AbbVie
Novo Nordisk
Actelion Pharmaceuticals
Sanofi
Biocon
Merck
Boehringer Ingelheim
AstraZeneca
CymaBay Therapeutics
Eli Lilly and Company
Frequently Asked Questions
Metabolic Disorders Therapeutics report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Metabolic Disorders Therapeutics report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Metabolic Disorders Therapeutics report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Salmeterol

The research report includes specific segments by region (country), by company, by Type and by Ap ... Read More